stars 1 stars 2 stars 3

T-Cypher was founded as a deep tech company with the mission of tackling one of the greatest unsolved challenges in human biology: How do we identify the specificities of the T cell populations that drive immune system failure, and use this knowledge to treat disease? Solving this problem would allow us to elucidate the origins of immune-mediated disease in humans, be transformative for drug development and directly lead to the design of next-generation therapeutics. To succeed in this mission, T-Cypher scientists designed, built and populated a unique data architecture that incorporates massive, diverse datasets relating to T cell immunology and cellular communication. This platform combines proprietary computational and wet-lab systems and today hosts data of the scale and quality required to understand T cell surveillance. We call the platform T-C Alpha. T-Cα effectively maps both sides of the T cell immune synapse. It maps the signature peptides our body uses in the communication of health and disease, and in parallel maps the reactivity of T cell repertoires. It does this at the scale, diversity and sensitivity of the human immune system. Today, T-Cα is a fully integrated discovery platform and machine learning engine profiling the human disease target space and its associated T cell reactivity. We use it to discover and develop next generation therapeutics for immune-mediated diseases.

T-Cypher Bio Questions

Rebecca Ashfield is the Chief Development Officer (CDO) of T-Cypher Bio.

35 people are employed at T-Cypher Bio.

T-Cypher Bio is based in Oxford, England.

Top T-Cypher Bio Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users